Combined results of HLA testing and prescription records
We investigated the status of the eight ADR-related HLA-alleles, seven
risk drugs, and target ADRs reported in 11,988 HLA-tested patients, as
shown in Figure 2 . In total, 4,092 patients (34.1%) had at
least one of the risk HLA alleles. The HLA-B*58:01 allele had the
highest frequency at 11.0% (Figure 2 ). In addition, 4,583
patients (38.2%) were prescribed at least one of the seven risk drugs.
The drug with the highest number of prescriptions was allopurinol (n =
2,782, 23.2%).
Some discrepancies in the reports of adverse events were identified
using SUPREME® and the ICSR. To resolve the
discrepancies, we regarded all cases of the reported drug-related side
effects in either of the two databases (SUPREME® and
ICSR) as true. Additionally, when the severity of ADRs reported in the
two databases did not match, we assumed that more severe events took
place. Data of a total of 580 patients with ADRs related to the seven
PGx drugs were evaluated.